Form 4/A for HAE HAEMONETICS CORP

Accepted 2025-06-13 00:00:00 ET · period of report 2025-05-16 · accession 0001127602-25-017492 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DA	2025-06-13	2025-05-16	HAE	Galvin Roy	EVP, Chief Commercial Off	A - Grant	—	+5,689	12.9K	+79%	—
DA	2025-06-13	2025-05-16	HAE	Galvin Roy	EVP, Chief Commercial Off	A - Grant	$0.00	+12.3K	12.3K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-05-16	A	A	5,689	—	12,932	D	—	—	(F1) The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. (F2) On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of RSUs awarded to be 6,755 instead of 5,689. This net decrease of 1,066 RSUs, and the corresponding change in securities beneficially owned by the reporting person, will be reflected in future filings by the reporting person. (F3) Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. (F4) This number includes unvested RSUs previously reported.
2	Derivative	Non-qualified Stock Option (Right to Buy)	2025-05-16	A	A	12,317	$0.00	12,317	D	$70.31 · — to 2032-05-16	12,317 Common Stock	(F5) On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of options awarded to be 14,626 instead of 12,317. This net decrease of 2,309 options will be reflected in future filings by the reporting person. (F6) Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.